An extension study to learn if Bimekizumab is safe and works as a long-term therapy in adults with moderate to severe hidradenitis suppurativa

You likely can't join if

• Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP).
• Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments. Note: For any study participant with an ongoing serious adverse event (SAE) from HS0003 (NCT04242446) or HS0004 (NCT04242498), or any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry or a history of serious infections in HS0003 or HS0004, the Medical Monitor must be consulted prior to the study participant's entry into HS0005, although the decision on whether to enroll the participant remains with the Investigator.
• Study participant has a positive or indeterminate interferon-gamma release assay (IGRA) in a feeder study, unless appropriately evaluated and treated.
• Study participant has ongoing or planned use of prohibited hidradenitis suppurativa (HS) or non-HS treatment.
• Study participant plans to participate in another study of a medicinal product or device under investigation during this study.
• In France and in Germany, at the time of implementation of Protocol Amendments 2.3/France and 2.4/Germany, respectively, and after the participant provides informed consent, eligible participants will continue for an additional 48‑week open‑label treatment period if the criteria specified in the Protocol are met. In France, Protocol Amendment 2.6/France has further extended the open-label treatment period for up to 40 additional weeks.